This expansion is part of NephroPlus’s efforts to grow internationally. Recently, the company also entered Saudi Arabia through a Joint Venture agreement. It now operates in five countries, focusing ...
The burden is particularly high in urban areas, where the prevalence reaches 15.2 percent compared to just 2.0 percent in ...
A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...
The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...
Stacker on MSN3d
Diabetes and other chronic conditions are becoming common. Here's how public health efforts can help bring rates down.Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves ...
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with ...
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...
Vantive, formerly the Baxter Kidney Care segment, launched as a new standalone vital organ therapy company following the completion of its ...
The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback